(NASDAQ: LGND) Ligand Pharmaceuticals's forecast annual revenue growth rate of 14.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.2%.
Ligand Pharmaceuticals's revenue in 2025 is $181,488,000.On average, 4 Wall Street analysts forecast LGND's revenue for 2025 to be $3,733,363,625, with the lowest LGND revenue forecast at $3,593,924,673, and the highest LGND revenue forecast at $3,854,974,766. On average, 4 Wall Street analysts forecast LGND's revenue for 2026 to be $4,430,037,444, with the lowest LGND revenue forecast at $4,110,815,434, and the highest LGND revenue forecast at $4,690,412,241.
In 2027, LGND is forecast to generate $5,275,797,298 in revenue, with the lowest revenue forecast at $4,736,332,361 and the highest revenue forecast at $5,902,085,991.